Essential Oils, Silver Nanoparticles and Propolis as Alternative Agents Against Fluconazole Resistant Candida albicans, Candida glabrata and Candida krusei Clinical Is

详细信息    查看全文

• 作者：Piotr Szweda ; Katarzyna Gucwa ; Ewelina Kurzyk…
• 关键词：Candida albicans ; Candida glabrata ; Candida krusei ; Essential oils ; Propolis ; Silver nanoparticles
• 刊名：Indian Journal of Microbiology
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：55
• 期：2
• 页码：175-183
• 全文大小：467 KB
• 参考文献：1. Calderone, RA (2002) Introduction and historical perspectives. Candida and Candidiasis. ASM Press, Washington, DC
  2. Pfaller, MA, Diekema, DJ (2004) Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42: pp. 4419-4431 CrossRef
  3. Silva, S, Negri, M, Henriques, M, Oliveira, R, Williams, DW, Azeredo, J (2012) Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev 36: pp. 288-305 CrossRef
  4. Low, Ch-Y, Rotstein, C (2011) Emerging fungal infections in immunocompromised patients. Med Rep 3: pp. 14
  5. Pfaller, MA, Diekema, DJ (2010) Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36: pp. 1-53 CrossRef
  6. Pfaller, MA, Diekema, DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: pp. 133-163 CrossRef
  7. Papon, N, Courdavault, V, Clastre, M, Bennett, RJ (2013) Emerging and emerged pathogenic Candida species: beyond the Candida albicans paradigm. PLoS Pathog 9: pp. e1003550 CrossRef
  8. Edlind, TD, Katiyar, SK (2010) Mutational analysis of flucytosine resistance in Candida glabrata. Antimicrob Agents Chemother 54: pp. 4733-4738 CrossRef
  9. Romanowska E (2008) Mechanizmy oporno?ci grzybów na leki przeciwgrzybicze/Fungal resistance mechanisms on antifungal agents. In: Dzier?anowska D (ed) Zaka?enia szpitalne. α -medica press, Bielsko-Bia?a, pp 497-07 (in Polish)
  10. Vermes, A, Guchelaar, HJ, Dankert, J (2000) Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 46: pp. 171-179 CrossRef
  11. Kurek, A, Grudniak, AM, Kraczkiewicz-Dowjat, A, Wolska, KI (2011) New antibacterial therapeutics and strategies. Pol J Microbiol 60: pp. 3-12
  12. Rajeshkumar, R, Sundararman, M (2012) Emergence of Candida spp. and exploration of natural bioactive molecules for anticandidal therapy—status quo. Mycoses 55: pp. e60-e73 CrossRef
  13. Franz, R, Ruhnke, M, Morschhaüser, J (1999) Molecular aspects of fluconazole resistance development in Candida albicans. Mycoses 42: pp. 453-458 CrossRef
  14. Zielinska, A, Kowalska, E, Sobczak, JW, Lacka, I, Gazda, M, Ohtani, B, Hupka, J, Zaleska, A (2010) Silver-doped TiO2 prepared by microemulsion method; surface properties, bio- and photoactivity. Sep Purif Tech 72: pp. 309-318 CrossRef
  Reference method for broth dilution antifungal susceptibility testing of yeasts: third edition (M27-A3). CLSI, Wayne
  15. Castro, PA, Bom, VL, Brown, NA, Almeida, RS, Ramalho, LN, Savoldi, M, Goldman, MH, Berretta, AA, Goldman, GH (2013) Identification of the cell targets important for propolis-induced cell death in Candida albicans. Fungal Genet Biol 60: pp. 74-86 CrossRef
  16. Romanowska E (2010) Zaka?enia grzybicze/Fungal infections. In: Piegdoń (ed) Piel?gniarstwo epidemiologiczne. Instytut Pomnik Centrum Zdrowia Dziecka, Warszawa, pp 58-5 (in Polish)
  17. Panacek, A, Kolar, M, Vecerova, R, Prucek, R, Soukupova, J, Krystof, V, Hamal, P, Zboril, R, Kvitek, L (2009) Antifungal activity of silver nanoparticles against Candida spp.. Biomaterials 30: pp. 6333-6340 CrossRef
  18. Kim, KS, Kim, YS, Han, I, Kim, M-H, Jung, MH, Park, H-K (2011) Quantitative and qualitative analyses of the cell death process in Candida albicans treated by anti
• 刊物主题：Microbiology; Medical Microbiology;
• 出版者：Springer India
• ISSN：0973-7715

文摘

Development of effective and safe therapeutic treatment of fungal infections remains one of the major challenge for modern medicine. The aim of presented investigation was to analyze the in vitro antifungal activity of selected essential oils, ethanolic extracts of propolis and silver nanoparticles dropped on TiO2 against azole-resistant C. albicans (n?=?20), C. glabrata (n?=?14) and C. krusei (n?=?10) clinical isolates. Among tested essential oils, the highest activity has definitely been found in the case of the oil isolated from the bark of Cinnamomum cassia, with MIC and MFC values for all tested strains in the range of 0.0006-.0097?% (v/v) and 0.0012-.019?% (v/v), respectively. High activity was also observed for the Lemon, Basil, Thyme, Geranium and Clove (from buds) essential oils. Significant differences in fungicidal activity have been observed in the case of four tested propolis samples. Only one of them revealed high activity, with MFC values in the range from 0.156 to 1.25?% (v/v). Satisfactory fungicidal activity, against C. albicans and C. glabrata isolates, was also observed in the case of silver nanoparticles, however C. krusei isolates were mostly resistant. We also revealed that constituents of most of essential oils and propolis as well as silver nanoparticles are not substrates for drug transporters, which belong to the most important factors affecting resistance of Candida spp. clinical isolates to many of conventional antimycotics. To conclude, the results of our investigation revealed that essential oils, propolis and silver nanoparticles represent high potential for controlling and prevention candidiasis.